Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis

CONCLUSION: Teduglutide treatment was associated with reductions in liver chemistries by week 24, which is beneficial for patients with SBS-IF beyond improvements in parenteral nutrition and/or intravenous fluid dependence. Future studies should examine how long-term teduglutide might mitigate the risk of liver disease in patients with SBS-IF.PMID:38491966 | DOI:10.1002/ncp.11139
Source: Nutrition in Clinical Practice - Category: Nutrition Authors: Source Type: research